Vaccination protects against invasive HPV‐associated cancers

Luostarinen, Tapio; Apter, Dan; Dillner, Joakim; Eriksson, Tiina; Harjula, Katja; Natunen, Kari; Paavonen, Jorma; Pukkala, Eero; Lehtinen, Matti

doi:10.1002/ijc.31231

Cited by 146 publications

(102 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, somewhat increased risk-taking behaviour in the Arms A/B in comparison to the Arm C was consistent. Lives in study community 3 Yes participants compared to Arm C participants in each corresponding HPV-vaccination status group (Table 1). Lives in study community 3 Yes participants compared to Arm C participants in each corresponding HPV-vaccination status group (Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…However, for HPV16 the decrease was found only in the C. trachomatis negatives. 3 Questionnaire data obtained at the age of 18.5-19 years and 22 years. The HPV51 and Table 1.…”

Section: Prevalence Ratios Of Hpv Typesmentioning

confidence: 99%

“…[1][2][3] In addition to the vaccine types HPV16/18, vaccination with the bivalent vaccine has been found to be cross-protective against HPV types 31, 33, 35 and 45, and to induce herd effects against HPV18/31/33/35 already with low to moderate gender-neutral vaccination coverage. [1][2][3] In addition to the vaccine types HPV16/18, vaccination with the bivalent vaccine has been found to be cross-protective against HPV types 31, 33, 35 and 45, and to induce herd effects against HPV18/31/33/35 already with low to moderate gender-neutral vaccination coverage.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Occurrence of human papillomavirus (HPV) type replacement by sexual risk‐taking behaviour group: Post‐hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV)

Gray

Luostarinen

Vänskä

et al. 2019

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Oncogenic non‐vaccine human papillomavirus (HPV) types may conceivably fill the vacated ecological niche of the vaccine types. The likelihood of this may differ by the risk of acquiring HPV infections. We examined occurrence of HPV types among vaccinated and unvaccinated subgroups of 1992–1994 birth cohorts with differing acquisition risks up to 9 years post‐implementation of HPV vaccination in 33 Finnish communities randomized to: Arm A (gender‐neutral HPV16/18 vaccination), Arm B (girls‐only HPV16/18 vaccination and hepatitis B‐virus (HBV) vaccination of boys), and Arm C (gender‐neutral HBV vaccination). Out of 1992–1994 born resident boys (31,117) and girls (30,139), 8,618 boys and 15,615 girls were vaccinated, respectively, with 20–30% and 50% coverage in 2007–2009. In 2010–2013, 8,868 HPV16/18 and non‐HPV vaccinated females, and in 2014–2016, 5,574 originally or later (2010–2013) HPV16/18 vaccinated females attended two cervical sampling visits, aged 18.5 and 22‐years. The samples were typed for HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68 using PCR followed by MALDI‐TOF MS. HPV prevalence ratios (PR) between Arms A/B vs. C were calculated for Chlamydia trachomatis positives (core‐group), and negatives (general population minus core group). At both visits the vaccine‐protected HPV type PRs did not significantly differ between the core‐group and non‐core group. Among the vaccinated 18‐year‐olds, HPV51 occurrence was overall somewhat increased (PRcore = 1.4, PRnon‐core. = 1.4) whereas the HPV52 occurrence was increased in the core‐group only (PRcore = 2.5, PRnon‐core = 0.8). Among the non‐HPV vaccinated 18‐year‐olds, the HPV51/52 PRs were higher in the core‐group (PRcore = 3.8/1.8, PRnon‐core = 1.2/1.1). The 22‐year‐olds yielded no corresponding observations. Monitoring of the sexual risk‐taking core‐group may detect early tendencies for HPV type replacement.

show abstract

Section: Resultsmentioning

confidence: 99%

“…However, for HPV16 the decrease was found only in the C. trachomatis negatives. 3 Questionnaire data obtained at the age of 18.5-19 years and 22 years. The HPV51 and Table 1.…”

Section: Prevalence Ratios Of Hpv Typesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Occurrence of human papillomavirus (HPV) type replacement by sexual risk‐taking behaviour group: Post‐hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV)

Gray

Luostarinen

Vänskä

et al. 2019

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…HPV types 6 and 11 are the major causes of genital warts and recurrent respiratory papillomatosis . HPV vaccines provide 90–100% protection against persistent infection by vaccine‐targeted HPV types and also protect against HPV‐associated invasive cancers . The vaccines are preventive, resulting in that vaccination prior to commencement of sexual activity is essential to gain the most benefit from HPV vaccination .…”

Section: Introductionmentioning

confidence: 99%

Human papillomavirus types in cervical dysplasia among young HPV‐vaccinated women: Population‐based nested case–control study

Kann

Hortlund

Eklund

et al. 2020

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Human papillomavirus (HPV) vaccines protect against infections with the most oncogenic HPV types, cervical intraepithelial neoplasia (CIN) and cervical cancer. We investigated whether development of cervical intraepithelial neoplasia (CIN) lesions in HPV‐vaccinated women is associated with vaccine‐targeted HPV types or not. Linkage of the Swedish vaccination and cervical screening registries identified all females born 1980–2000 who had been HPV vaccinated before December 31, 2014 (n = 305,320) and had attended cervical screening in 2006–2018 (n = 79,491). We further selected women HPV vaccinated below 17 years of age and screened in the capital region (n = 5,874). Among those, 125 developed CIN and had a cervical cryopreserved sample available (42.5% of all eligible CIN cases). After 1:2 matching to disease‐free HPV vaccinated controls (n = 242), samples were analyzed for HPV DNA and associations between HPV type and CIN diagnosis were estimated with conditional logistic regression. Vaccine‐targeted HPV types were rare among both CIN cases (2.4% HPV16, 0.8% HPV18) and their matched controls (0.4% HPV16 and 18). No woman had HPV6 or 11. The CIN lesions were associated with the nonvaccine HPV types 31, 33, 42, 45, 51, 52, 56, 59 and 66. CIN lesions among young HPV vaccinated women are mostly attributable to infection with nonvaccine HPV types. The phenomenon may be important for surveillance and design of cervical cancer control strategies.

show abstract

“…Согласно анализу данных национального онкологического реги-стра Финляндии, где национальная програма вакцинации стартовала в 2013 г., установлена 100% эффективность вакцинации против ВПЧ в отношении возникновения инвазивных ВПЧ-ассоциированных типов рака среди вакцинированных женщин 14-19 лет в сравнении с жен-щинами, которым не проводилась вакцинация против ВПЧ [30].…”

Section: африканский регионunclassified